GlassScriptPhysician profile
Lance J Miller
NPI 1568411999
$589.02
in general payments reported to CMS, 2019-2025
15 companies · $79.83 in 2025
The $79.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.36 · 2020: $37.74 · 2021: $12.01 · 2022: $75.71 · 2023: $134 · 2024: $185 · 2025: $79.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $128.95 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $77.69 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $64.58 | 2023-2024 | Wegovy |
| Pfizer INC. | $62.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $44.88 | 2019-2024 | Shingrix |
| Dexcom, INC. | $37.49 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $27.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.47 | 2019 | |
| Amarin Pharma, INC. | $21.37 | 2020 | |
| Exact Sciences Corporation | $20.77 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $20.54 | 2022 | |
| Merck Sharp & Dohme LLC | $20.28 | 2024 | Gardasil, M-M-R II, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $15.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.67 | 2019 | |
| Esperion Therapeutics, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.